Teva Pharmaceutical Industries Limited Sponsored ADR Stock

$15.29

0.00% today

NYSE, Apr 02, 10:10 pm CET

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$15.29

+7.17 88.30% 5Y

NYSE, Closing price Wed, Apr 02 2025

+0.00 0.00%

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$17.52b
Enterprise Value	$32.73b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	16.05
EV/Sales (TTM) EV/Sales	1.98
P/S ratio (TTM) P/S ratio	1.06
P/B ratio (TTM) P/B ratio	3.22
Revenue growth (TTM) Revenue growth	4.34%
Revenue (TTM) Revenue	$16.53b
EBIT (operating result TTM) EBIT	$3.35b
Free Cash Flow (TTM) Free Cash Flow	$2.04b
Cash position	$3.30b
EPS (TTM) EPS	$-1.45
P/E forward	7.72
P/S forward	1.02
EV/Sales forward	1.90
Short interest	3.05%

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Get Started for Free Today

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

8x Buy

73%

3x Hold

27%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Buy

73%

Hold

27%

Analyst Estimates with Stock Price Targets

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	16,531 16,531	4% 4% 100%
- Direct Costs	8,480 8,480	3% 3% 51%
Gross Profit	8,051 8,051	5% 5% 49%
- Selling and Administrative Expenses	2,642 2,642	13% 13% 16%
- Research and Development Expense	999 999	5% 5% 6%
EBITDA	4,410 4,410	1% 1% 27%
- Depreciation and Amortization	1,059 1,059	8% 8% 6%
EBIT (Operating Income) EBIT	3,351 3,351	5% 5% 20%
Net Profit	-1,638 -1,638	211% 211% -10%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

2 days ago

New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS...

Neutral

The Motley Fool

●

5 days ago

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

It's hard to believe, but the first quarter of 2025 is rapidly coming to a close. After doing a quick portfolio checkup, I found that I have stocks that have gained as much as 40% already this year, but I also have a few that are down nearly 30%.

Neutral

GlobeNewsWire

●

6 days ago

Teva Releases Q1 2025 Aide Memoire

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website.

More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office	Israel
CEO	Richard Francis
Employees	36,167
Founded	1901
Website	www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now